Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

utions received a major boost. While all three of our in-clinic molecules performed admirably, Btk Inhibitor PCI-32765 was in all forms of measurement truly outstanding. We plan to initiate our first Phase III trial for 32765 in this fiscal year ending June 30, 2012. We currently also plan to initiate a second Phase III during calendar year 2012. In terms of human and financial capital we are in good shape. Opportunity attracts great people and so it is the case with us. Our expanding team continues to be very focused on building a viable pharmaceutical company that makes a truly significant difference for the better." said Bob Duggan, CEO and Chairman of the Board. "We at Pharmacyclics take great pride in our accomplishments over the past few years and we maintain a keen sense of obligation and enthusiasm as we create our future."

Recent Developments & HighlightsBruton's Tyrosine Kinase (Btk) Inhibitor for Oncology

  • Results from our Phase IB/II trial of PCI 32765 in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) were presented at an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois in June 2011. As reported at the meeting, treatment with PCI-32765 was generally well-tolerated.  The most common adverse events were Grade 1 (mild) or Grade 2 (moderate) diarrhea, fatigue, and nausea. Durable anti-tumor activity was also observed; 3 of 83 patients who were evaluable at the time of presentation had experienced disease progression.  An abstract with an updated analysis of this trial has been submitted for the 2011 American Society of Hematology (ASH) Annual Meeting to be held in San Diego in December, 2011.

  • In August 2011, we entered into a five-year Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765.  Under the Agreement, the NCI's Division of Cancer
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
    2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
    3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
    4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
    5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
    6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
    7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
    9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
    10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
    11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/19/2014)... October 19, 2014 Große ... Das Problem dabei ist, dass große Pharmafirmen ... Kompetenz zu teilen. Es war deshalb ... wir uns umso mehr, dass es uns gelungen ... bei Kühlketten aufzuschreiben - mit einem Vorbehalt - ...
    (Date:10/17/2014)... HILL, N.C. , Oct. 17, 2014 /PRNewswire/ ... insights is a critical success factor in today,s ... must develop market research organizations that effectively and ... location, specialty or service area. ... create value and earn recognition from internal clients ...
    (Date:10/17/2014)... Oct. 17, 2014 UBM Medica US announces that ... online community and information resource for neurologists and other healthcare ... Alzheimer disease , with discussions of the latest developments ... million Americans have Parkinson disease , more than the total ... Lou Gehrig disease. Diagnosis can be difficult because there ...
    Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
    ... March 19, 2012  BioStorage Technologies, a global provider ... cold chain logistics for the bioscience industry, announced ... webinar titled, "Comprehensive Sample Management: Leveraging an Onsite ... Thursday, March 22, from 11:00 AM to 12:30 ...
    ... Reportlinker.com announces that a new market research ... Branded Prescription Pharmaceutical Sales ... http://www.reportlinker.com/p0799256/Branded-Prescription-Pharmaceutical-Sales-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... achieved sales of $558bn having experienced a ...
    Cached Medicine Technology:BioStorage Technologies to Host Live Webinar on Optimizing the Value of Sample Assets 2Branded Prescription Pharmaceutical Sales Outlook to 2016 2Branded Prescription Pharmaceutical Sales Outlook to 2016 3Branded Prescription Pharmaceutical Sales Outlook to 2016 4Branded Prescription Pharmaceutical Sales Outlook to 2016 5
    (Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today announced ... module enables easy administration and routing of follow-up items ... This application allows users such as Therapists to assign ... item to a specific client, categorize tasks the way ... for follow-ups. It's designed to enable easy access ...
    (Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
    (Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
    (Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
    (Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its ... GoDaddy and HostMonster are the best VPS hosting ... Server) is the method of partitioning a physical ... has the appearance and capabilities of running on ... site pays close attention to VPS products and ...
    Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
    ... ... ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. ... the 2009 American Society of Hematology ("ASH") Annual Meeting updated results ... pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive ...
    ... of Chicago have discovered a technique that is able to ... habitual snoring by screening their urine. "These findings ... test that could detect OSA in snoring children. This would ... children who snore, only about 20 to 30 percent of ...
    ... , OAK BROOK, Ill., Dec. 7 ... center (AMC) members for their achievements in UHC,s Supply ... are noted for modeling best practices in supply chain ... , The winners were determined using 2008 data and ...
    ... , , Consumers ... SILVER SPRING, Md., Dec. 6 The U.S. Food and Drug ... San Antonio Bay on or after Nov. 16 due to reports ... from this area, which is located on the Gulf of Texas. ...
    ... have discovered that the loss of a key segment of DNA ... to show that this kind of genetic alteration can cause obesity. ... study, led by Dr Sadaf Farooqi from the University of Cambridge ... at 300 children with severe obesity. The team scanned each ...
    ... find signs of feline DNA in virus , SUNDAY, Dec. 6 ... might be found in a tiger that lived thousands or millions ... virus took on a bit of a tiger,s genetic material, scientists ... to this day. That tiger, in fact, may have bitten a ...
    Cached Medicine News:Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Urine test for pediatric obstructive sleep apnea possible 2Health News:Recognized Top Performers in UHC Supply Chain 2Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: